These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20831715)

  • 1. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
    Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
    Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I; Guyette E; Watkins J; Danielson D; Gross D; Yeung K
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
    DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
    Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
    Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
    Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
    Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
    Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time trends in medication use and expenditures in older patients with rheumatoid arthritis.
    Harrold LR; Peterson D; Beard AJ; Gurwitz JH; Briesacher BA
    Am J Med; 2012 Sep; 125(9):937.e9-15. PubMed ID: 22682794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis.
    Weycker D; Yu EB; Woolley JM; Oster G
    Clin Ther; 2005 May; 27(5):646-56. PubMed ID: 15978314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
    Harrison DJ; Huang X; Globe D
    Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
    Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
    Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.